CN1401326A - Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof - Google Patents
Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof Download PDFInfo
- Publication number
- CN1401326A CN1401326A CN 02135573 CN02135573A CN1401326A CN 1401326 A CN1401326 A CN 1401326A CN 02135573 CN02135573 CN 02135573 CN 02135573 A CN02135573 A CN 02135573A CN 1401326 A CN1401326 A CN 1401326A
- Authority
- CN
- China
- Prior art keywords
- total flavones
- diseases
- cardiovascular
- ethanol
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A total flavone medicine containing two dihydroflavone compounds e.g. naringenin-7-O-glucoside for treating ischemic cardiovascular and cerebrovascular diseases is prepared from the dried herb of rupestrine dragonhead trough extracting and chromatographic separation.
Description
(1) technical field
The present invention relates to total flavones that a kind of plant amedica extracts and preparation method thereof and application, be specifically related to a kind of preparation of the total flavones of diseases of cardiovascular and cerebrovascular systems, preparation technology of preparation for the treatment of.
(2) background technology
Along with the aging of society, the hazardness of cardiovascular and cerebrovascular disease is noticeable day by day, and the generation of diseases such as ischemic cardio cerebrovascular diseases, angina pectoris, myocardial infarction, cerebral infarction is all relevant with myocardial ischemia, platelet function abnormality; PAF (platelet activating factor) is a kind of lipid medium with extensive biological action, in the generation of multiple pathological process and development, play an important role, can activate platelet, the gathering of induced platelet, cause thrombosis, thereby cause myocardial infarction or cerebral infarction.Herba Dracocephali Rupestris's total flavones is to extract, separate the effective site that obtains on the ground the herb from labiate Herba Dracocephali Rupestris (Dracocephalum rupestra Hance), its main component is flavanone kind composition naringenin-7-O-glucoside and bear's weed element-7-O-glucoside, the expansible arteria coronaria of this effective site of evidence significantly increases coronary flow; Have significant PAF antagonism, obvious inhibitory action is arranged, have antioxidation, remove free radical and anti-protein saccharification, can treat ischemic cardio cerebrovascular diseases, angina pectoris, myocardial infarction, cerebral infarction for the inductive platelet aggregation of PAF.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of total flavones for the treatment of diseases of cardiovascular and cerebrovascular systems and preparation method thereof and application are provided.
The total flavones that the present invention treats diseases of cardiovascular and cerebrovascular systems is a raw material with the dry herb in Herba Dracocephali Rupestris ground, be prepared from by solvent extraction, precipitate with ethanol or water precipitating, chromatography and purification, naringenin in the gained total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 70%, and the two ratio is 0.50~0.80.
The total flavones preparation method that the present invention treats diseases of cardiovascular and cerebrovascular systems comprises the steps: that former plant is through after pulverizing, with water, methanol, ethanol, 30~95% aqueous methanol, 30~95% aquiferous ethanol, acetone, 30~95% aqueous acetone or ethyl acetate are for extracting solvent, heating extraction, the solvent for use amount is 8~15: 1 with the raw material weight ratio, can repeat to extract 1~3 time, remove medicinal residues, filtrate by precipitate with ethanol or water precipitating method, is removed some impurity after being concentrated into proportion 1.13~1.17 under normal pressure or the reduced pressure, supernatant concentration is to proportion 1.10~1.15, carry out column chromatography, use the eluent eluting, steaming desolventizes, 70~95% dissolve with ethanols, place, crystallize, crystallization is with 70~95% ethyl alcohol recrystallizations, the leaching crystallization, promptly.Below all be weight percentage.
The total flavones preparation method concrete steps of treatment diseases of cardiovascular and cerebrovascular systems of the present invention are as follows:
1. solvent extraction
Former plant is through after pulverizing, water, methanol, ethanol or contain water beetle, ethanol (30~95%), acetone, aqueous acetone (30~95%) or ethyl acetate, heating extraction (comprising backflow), the solvent for use amount is 8~15: 1 with former plant weight ratio, with 12 times of quantity of solvent the bests, can repeat to extract 1~3 time, remove medicinal residues, filtrate is concentrated into proportion 1.13~1.17 under normal pressure or reduced pressure.
Solvent extraction is with 60~95% aqueous alcohol or 30%~50% aqueous acetone reflux, extract,, and quantity of solvent is 12 times of raw material.
2. precipitate with ethanol or water precipitating
Above-mentioned concentrated solution precipitate with ethanol or water precipitating are removed impurity.With the alcohol deposition method that passes through of water extraction,, remove impurity with the method for passing through water precipitating of organic solvent extraction.
Usedly in the alcohol deposition method contain water beetle, concentration of alcohol is 50%~80%, and is best with 70%
3. column chromatography
Above-mentioned supernatant concentration to proportion 1.10~1.15, is carried out silica gel (column chromatography is used), polyamide (1340 order) or macroporous resin column chromatography.Silica gel column chromatography chloroform-methanol eluting; Polyamide and macroporous resin chromatography be with water-ethanol or methanol gradient elution, collects 8: 2~6: 4 eluting parts of chloroform-methanol or 30%~50% ethanol or methanol-eluted fractions part, solvent evaporated.
4. purification
With above-mentioned steps product with 70~95% dissolve with ethanols, place crystallize.Crystallization is again with 70~95% ethyl alcohol recrystallizations, and the leaching crystallization promptly gets total flavones.
Naringenin in the inventive method gained total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 70%, and the two ratio is 0.30~0.80.
The application of the total flavones of treatment diseases of cardiovascular and cerebrovascular systems of the present invention is as follows: add relevant auxiliary materials in total flavones, can be made into tablet, capsule and freeze dried injection.
Concrete application process is as follows:
1) making of tablet or capsule, all by the percentage by weight of total flavones total amount:
Described total flavones, the diluent that adds 2~5 times of weight, as starch, Icing Sugar, dextrin, microcrystalline Cellulose, 5%~10% structure wetting agent such as water, ethanol, 4%~15% disintegrating agent, as carboxymethyl starch sodium, wet granulation routinely, dry back granulate adds 0.5%~3% lubricant again, as magnesium stearate, Pulvis Talci, tabletting or incapsulate shell.
2) making of injection freeze-dried products, all by the percentage by weight of total flavones total amount:
Described total flavones adds mannitol as the skeleton agent, and the 2-HP-is dissolved in 2~3 times of amounts (weight/volume) water for injection, packing, lyophilization as solubilizing agent.
Above-mentioned mannitol and total flavones weight ratio are 1~3: 1, and 2-HP-and total flavones weight ratio are 1~5: 1.
The total flavones of treatment diseases of cardiovascular and cerebrovascular systems of the present invention and preparation thereof are used for the treatment of ischemic cardio cerebrovascular diseases, angina pectoris, myocardial infarction, cerebral infarction.
The drug effect of treatment diseases of cardiovascular and cerebrovascular systems structure total flavones of the present invention is as follows:
Influence to the isolated rat coronary flow: get rat and tap the head and cause dusk, cut off the thoracic cavity, expose heart, cut off pericardium, gently worry dirtyly, cut off the vascular tissue that links to each other with heart, take out heart, put into 4 ℃ of oxygen-saturated Rockwell liquid immediately, extrude the surplus blood of heart, find the aorta stump, aorta is enclosed within on the aortic cannulation, after ligation is fixing, stablized 10 minutes, 37 ± 1 ℃ of perfusate temperature, pressure 50mmH2O, oxygenation.Measure the per minute flow, flow was close in continuous 3 minutes, and its meansigma methods can be used as the minimum flow before the administration.Give injection dried frozen aquatic products solution 0.2ml successively from side pipe, measure after each administration the flow of per minute in continuous 6 minutes, find out maximum, the maximum value added of flow behind the calculating medicine, calculate the coronary flow increment rate, the result shows that total flavones can significantly increase coronary flow.
Anti-PAF effect is observed: new zealand rabbit, body weight is between 2.5~3Kg, gather 30ml auricular vein blood, anti-condensation with 1: 9 (V/V) 3.8% sodium citrate, platelet blood plasma (PRP) is rich in the centrifuging preparation, measures in PRP to add 25 μ l total flavones aqueous solutions (1mg/ml) in the pipe, 37 ℃ of deposited 1min that educate, add platelet aggregation derivant PAF, adopt the Born turbidimetry, measure platelet aggregation.The result shows that total flavones has obvious inhibitory action to the inductive platelet aggregation of PAF.
The total flavones that the present invention treats diseases of cardiovascular and cerebrovascular systems has the PAF antagonism, can suppress the inductive platelet aggregation of PAF, coronary artery dilating, increase coronary flow, have antioxidation, remove free radical and anti-protein saccharification, be used for the treatment of ischemic cardio cerebrovascular diseases, angina pectoris, myocardial infarction, cerebral infarction, have good effect, the advantage that cost is low.
(4) specific embodiment
Embodiment 1:
The Herba Dracocephali Rupestris goes up herb dryly, adds 12 times of water gagings, and boiling was extracted 2 hours, extract altogether 2 times, extracting solution is concentrated into proportion 1.15, adds ethanol to determining alcohol 70%, precipitates 24 hours, supernatant concentration is to the thickness paste, add 2 times of amount column chromatography silica gels and mix vacuum drying, porphyrize thoroughly, the chromatographic column of packing into, chloroform-methanol is washed and is looked askance noresidue to the eluent evaporate to dryness at 9: 1, and 6: 4 eluting of chloroform-methanol are eluted to eluent TLC (thin layer chromatography) and detect no tested speckle, eluent steams and desolventizes, 95% dissolve with ethanol, crystallize leaches crystallization, ethyl alcohol recrystallization gets Herba Dracocephali Rupestris's total flavones.
Naringenin in the total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 75%, and the two ratio is 0.70.
Embodiment 2:
The Herba Dracocephali Rupestris goes up herb dryly, add 12 times of water gagings, boiling was extracted 2 hours, extract altogether 2 times, extracting solution is concentrated into proportion 1.15, adds ethanol to determining alcohol 70%, precipitates 24 hours, supernatant concentration is to flowing soaking paste, add the top of pre-packed polyamide column (polyamide and crude drug weight ratio are 1: 2), water elution is colourless to eluent, 30% ethanol elution, be eluted to eluent TLC (thin layer chromatography) and detect no tested speckle, eluent is used 95% dissolve with ethanol after removing solvent under reduced pressure, and crystallize leaches crystallization, ethyl alcohol recrystallization gets Herba Dracocephali Rupestris's total flavones.
Naringenin in the total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 73%, and the two ratio is 0.55.
Embodiment 3:
The Herba Dracocephali Rupestris goes up herb dryly, add 12 times of water gagings, boiling was extracted 2 hours, extract altogether 2 times, extracting solution is concentrated into proportion 1.15, adds ethanol to determining alcohol 70%, precipitates 24 hours, supernatant concentration is to flowing soaking paste, add the top of pre-packed macroporous resin column (macroporous resin and crude drug weight ratio are 1: 1), water elution is colourless to eluent, 30% ethanol elution, be eluted to eluent TLC (thin layer chromatography) and detect no tested speckle, eluent is used 95% dissolve with ethanol after removing solvent under reduced pressure, and crystallize leaches crystallization, ethyl alcohol recrystallization gets Herba Dracocephali Rupestris's total flavones.
Naringenin in the total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 78%, and the two ratio is 0.55.
Embodiment 4:
The Herba Dracocephali Rupestris goes up herb dryly, add 12 times of amount 70% ethanol, reflux, extract, 2 hours, extract altogether 2 times, extracting solution is concentrated into flowing soaking paste, and the water of adding and medical material weight equivalent precipitates 24 hours, supernatant concentration is to flowing soaking paste, add the top of pre-packed polyamide column (polyamide and medical material weight ratio are 1: 2), water elution is colourless to eluent, 30% ethanol elution, be eluted to eluent TLC (thin layer chromatography) and detect no tested speckle, eluent is used 95% dissolve with ethanol after removing solvent under reduced pressure, and crystallize leaches crystallization, ethyl alcohol recrystallization gets Herba Dracocephali Rupestris's total flavones.
Naringenin in the total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 71%, and the two ratio is 0.58.
Embodiment 5:
The Herba Dracocephali Rupestris goes up herb dryly, adds 12 times of amount 50% acetone, reflux, extract, 2 hours, extract altogether 2 times, extracting solution is concentrated into flowing soaking paste, and the water of adding and medical material weight equivalent precipitates 24 hours, supernatant concentration is to the thickness paste, add 2 times of amount column chromatography silica gels and mix vacuum drying, porphyrize thoroughly, the chromatographic column of packing into, chloroform-methanol is eluted to noresidue behind the eluent evaporate to dryness at 9: 1, and 6: 4 eluting of chloroform-methanol are eluted to eluent TLC and detect no tested speckle, eluent steams and desolventizes, 95% dissolve with ethanol, crystallize leaches crystallization, ethyl alcohol recrystallization gets Herba Dracocephali Rupestris's total flavones.
Naringenin in the total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 76%, and the two ratio is 0.70.
Embodiment 6:
The Herba Dracocephali Rupestris goes up herb dryly, add 12 times of amount 70% ethanol or 50% acetone, reflux, extract, 2 hours, extract altogether 2 times, extracting solution is concentrated into flowing soaking paste, and the water of adding and medical material weight equivalent precipitates 24 hours, supernatant concentration is to flowing soaking paste, add the top of pre-packed macroporous resin column (macroporous resin and medical material weight ratio are 1: 1), water elution is colourless to eluent, 30% ethanol elution, be eluted to eluent TLC and detect no tested speckle, eluent is used 95% dissolve with ethanol after removing solvent under reduced pressure, and crystallize leaches crystallization, ethyl alcohol recrystallization gets Herba Dracocephali Rupestris's total flavones.
Naringenin in the total flavones-7-O-glucoside and bear's weed element-two kinds of flavanone content of 7-O-glucoside are not less than 79%, and the two ratio is 0.78.
Embodiment 7: total flavones is used for tablet
The total flavones 20g of embodiment 1 gained adds starch 40g, dextrin 25g, and cane sugar powder 10g, mixing is made granule, and is dry below 60 ℃, and granulate adds Pulvis Talci 0.3g, and mixing is pressed into 1000, promptly.
Embodiment 8: total flavones is used for capsule
The total flavones 20g of embodiment 3 gained adds starch 40g, dextrin 25g, and microcrystalline Cellulose 10g, mixing is made granule, and is dry below 60 ℃, and granulate adds magnesium stearate 0.2g, and mixing incapsulates shell, promptly.
Embodiment 9: total flavones is used for the injection freeze-dried products
The total flavones 10g of embodiment 4 gained with equivalent mannitol mixing, adds injection water 100ml, and 80 ℃ of heating make into suspension, and are standby; Take by weighing the 20g2-HP-, add injection water 100ml dissolving, under 80 ℃ of stirring conditions suspension is slowly added in the 2-HP-, adding active carbon stirred 30 minutes for 0.05%80 ℃, filtering with microporous membrane, filtrate is settled to 300ml, packing, loading amount 3ml/ props up, and lyophilization promptly.
Claims (10)
1, a kind of total flavones for the treatment of diseases of cardiovascular and cerebrovascular systems, it is characterized in that, by the Herba Dracocephali Rupestris is raw material, be prepared from by solvent extraction, precipitate with ethanol or water precipitating, chromatography and purification, gained total flavones main component is naringenin-7-O-glucoside, bear's weed element-two kinds of flavanone constituents of 7-O-glucoside, its total amount is greater than 70%, and its ratio is 0.30~0.80.
2, the preparation method of the total flavones of the described treatment diseases of cardiovascular and cerebrovascular systems of a kind of claim 1, comprise the steps: that former plant is through after pulverizing, with water, methanol, ethanol, 30~95% aqueous methanol, 30~95% aquiferous ethanol, acetone, 30~95% aqueous acetone or ethyl acetate are for extracting solvent, heating extraction, the solvent for use amount is 8~15: 1 with the raw material weight ratio, repeat to extract 1~3 time, remove medicinal residues, filtrate is after being concentrated into proportion 1.13~1.17 under normal pressure or the reduced pressure, by precipitate with ethanol or water precipitating method, the removal of impurity, supernatant concentration are carried out column chromatography to proportion 1.10~1.15, the eluent eluting, steaming desolventizes, and 70~95% dissolve with ethanols are placed, crystallize, crystallization is with 70~95% ethyl alcohol recrystallizations, the leaching crystallization, promptly.
3, a kind of preparation method for the treatment of the total flavones of diseases of cardiovascular and cerebrovascular systems according to claim 2, it is characterized in that extracting solvent is 60~95% aqueous alcohol or 30%~50% acetone reflux, extract,, quantity of solvent is 12 times of raw material.
4, a kind of preparation method for the treatment of the total flavones of diseases of cardiovascular and cerebrovascular systems according to claim 2 is characterized in that precipitate with ethanol is 50%~80% with aqueous methanol, concentration of alcohol.
5, a kind of preparation method for the treatment of the total flavones of diseases of cardiovascular and cerebrovascular systems according to claim 2 is characterized in that a kind of in column chromatography available silicon plastic column chromatography, macroporous resin column chromatography or the polyamide column chromatography.
6, according to claim 2 or 5 described a kind of preparation methoies for the treatment of the total flavones of diseases of cardiovascular and cerebrovascular systems, it is characterized in that silica gel column chromatography adopts the chloroform-methanol gradient elution, collect 8: 2~6: 4 eluting parts of chloroform-methanol, macroporous resin and polyamide adopt water-ethanol or methanol gradient elution, collect 30%~50% ethanol or methanol-eluted fractions part.
7, the application of the total flavones of the described treatment diseases of cardiovascular and cerebrovascular systems of claim 1 adds relevant pharmaceutical aids in total flavones, make tablet, capsule and injection.
8, a kind of application for the treatment of the total flavones of diseases of cardiovascular and cerebrovascular systems according to claim 7 is characterized in that: the making of tablet or capsule, all by the percentage by weight of total flavones total amount:
Described total flavones, the diluent that adds 2~5 times of weight, as starch, Icing Sugar, dextrin, microcrystalline Cellulose, 5%~10% wetting agent such as water, ethanol, 4%~15% disintegrating agent, as carboxymethyl starch sodium, wet granulation routinely, dry back granulate adds 0.5%~3% lubricant again, as magnesium stearate, Pulvis Talci, tabletting or incapsulate shell.
9, a kind of application for the treatment of the total flavones of diseases of cardiovascular and cerebrovascular systems according to claim 7 is characterized in that: the making of injection freeze-dried products, all by the percentage by weight of total flavones total amount:
Described total flavones adds mannitol as the skeleton agent, and the 2-HP-is dissolved in 2~3 times of amount waters for injection, weight/volume, packing, lyophilization as solubilizing agent.
10, a kind of application for the treatment of the total flavones of diseases of cardiovascular and cerebrovascular systems according to claim 9, it is characterized in that: mannitol and total flavones weight ratio are 1~3: 1,2-HP-and total flavones weight ratio are 1~5: 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02135573 CN1228052C (en) | 2002-09-26 | 2002-09-26 | Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02135573 CN1228052C (en) | 2002-09-26 | 2002-09-26 | Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1401326A true CN1401326A (en) | 2003-03-12 |
CN1228052C CN1228052C (en) | 2005-11-23 |
Family
ID=4748259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02135573 Expired - Fee Related CN1228052C (en) | 2002-09-26 | 2002-09-26 | Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1228052C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101219161B (en) * | 2007-12-25 | 2011-09-14 | 新疆维吾尔自治区药物研究所 | Dracocephalum moldavica extract and dracocephalum moldavica dropping pills, and method of preparing the same |
CN103308643A (en) * | 2012-03-15 | 2013-09-18 | 瑞阳制药有限公司 | Quality control method of dracocephalum rupestre hance total flavonoids and preparations thereof |
CN108623548A (en) * | 2018-05-02 | 2018-10-09 | 齐齐哈尔大学 | The method and its application of hand-type eriodictyol in a kind of separation peanut shell |
CN113207984A (en) * | 2021-03-31 | 2021-08-06 | 山西农业大学 | Preparation method of rock blue instant tea powder |
CN115215827A (en) * | 2022-08-04 | 2022-10-21 | 苏州永健生物医药有限公司 | Method for enriching and preparing eriodictyol from mohair weeds |
-
2002
- 2002-09-26 CN CN 02135573 patent/CN1228052C/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101219161B (en) * | 2007-12-25 | 2011-09-14 | 新疆维吾尔自治区药物研究所 | Dracocephalum moldavica extract and dracocephalum moldavica dropping pills, and method of preparing the same |
CN103308643A (en) * | 2012-03-15 | 2013-09-18 | 瑞阳制药有限公司 | Quality control method of dracocephalum rupestre hance total flavonoids and preparations thereof |
CN108623548A (en) * | 2018-05-02 | 2018-10-09 | 齐齐哈尔大学 | The method and its application of hand-type eriodictyol in a kind of separation peanut shell |
CN108623548B (en) * | 2018-05-02 | 2022-05-06 | 齐齐哈尔大学 | Method for separating chiral eriodictyol from peanut shells and application of method |
CN113207984A (en) * | 2021-03-31 | 2021-08-06 | 山西农业大学 | Preparation method of rock blue instant tea powder |
CN115215827A (en) * | 2022-08-04 | 2022-10-21 | 苏州永健生物医药有限公司 | Method for enriching and preparing eriodictyol from mohair weeds |
CN115215827B (en) * | 2022-08-04 | 2024-02-06 | 苏州永健生物医药有限公司 | Method for preparing eriodictyol from eriodictyol in enrichment mode |
Also Published As
Publication number | Publication date |
---|---|
CN1228052C (en) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102643322B (en) | Method for simultaneously preparing pedunculoside and syringin | |
CN101396384B (en) | Asiatic centella extract and preparation methode thereof | |
CN102552396B (en) | Salvia miltiorrhiza Bunge var alba total phenolic acid extract, preparation method and application | |
CN100439319C (en) | Method for preparing salviol acid A | |
CN101343225A (en) | Preparation method for high-purity di-coffee mesitoyl quinine acid compounds | |
CA2486378A1 (en) | Preparation and application of total salvianolic acid | |
CN1228052C (en) | Total flavone for treating cadiovasular cerebrovasular system diseases, and preparing method and use thereof | |
CN1436553A (en) | Method of extracting effective component in red sage | |
CN1943569B (en) | Chinese medicine active component composition and its preparing method and use | |
CN110917181B (en) | Separation method and application of licochalcone B | |
CN101574410A (en) | Effective components of peony leaves as well as preparation method and application thereof | |
CN101190906B (en) | Method for preparing carthamin yellow carthamus B and application thereof | |
CN1187069C (en) | Method for extracting coxtex mouten total glucoside for treating hepatitis | |
CN113913029B (en) | Method for preparing effective components of gardenia jasminoides ellis | |
CN1209155C (en) | Balsam pear products containing multiple hypoglycemic active composition and preparation thereof | |
CN108542926A (en) | The preparation method and pharmaceutical composition of a kind of purslane extract and its application | |
CN115010618A (en) | Separation and purification method of aureoyl amide alcohol ester capable of reducing uric acid and application thereof | |
CN104491048A (en) | Loquat leaf total sesquiterpene extract as well as preparation method and application thereof | |
CN110950917B (en) | Separation method and application of apiose isoliquiritin | |
FI64892C (en) | FRAMEWORK FOR ANTI-SORGHY EFFECTS | |
CN1081922C (en) | Medicinal composition containing ginsenoside Re, preparation and usage thereof | |
CN110721128A (en) | Cortex Mori extract and its preparation method | |
CN112661799B (en) | Method for separating and purifying protopteridoside in pteridophyte | |
JP2579255B2 (en) | Angiotensin converting enzyme activity inhibitor from Tochu leaf extract | |
CN101721468B (en) | Method for preparing salvianolic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051123 Termination date: 20170926 |